Latest News

Linagliptin improved albuminuria but effect on eGFR and CV risk in patients with diabetes

Diabetes mellitus is a significant and growing health problem which contributes significantly to the prevalence of chronic kidney disease (CKD). According to the ERA-EDTA Registry, nearly a quarter (23 percent) of all patients who started renal replacement therapy in 2016 were patients with diabetes. The underlying idea of the study, which has been presented as a late breaking clinical trial at the ERA-EDTA congress in Budapest today, was to assess the potential of the DPP-4 inhibitor linagliptin (LINA), an oral diabetes drug, to reduce the burden of CKD and cardiac complications as secondary diseases in people with diabetes. Only a few weeks ago it had been shown that SGLT2 inhibitors, another class of diabetes drugs, could slow CKD progression in this patient group.

Source link

Related posts

STAT Plus: A former Taro Pharma executive is indicted in generic price-fixing probe


Riassunto: Terns Pharmaceuticals ottiene dalla FDA la designazione di farmaco soggetto a procedura abbreviata per TERN-101, agonista del recettore FXR per il trattamento della NASH


Study reveals fresh insights into how new disease-causing strains of bacteria emerge


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy